CADILA HEALTHCARE LTD. - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate10-12-2021
10-12-2021
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus announces EPICS-IIITM Phase 2(b)/3 adaptive pivotal clinical trial of Saroglitazar Mg in PBC10-12-2021
CADILA HEALTHCARE LTD. - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate08-12-2021
Zydus Cadila's monoclonal antibody effective against multiple variants of SARS-CoV-2: ICMR
The study was conducted on Syrian Hamsters and published in the international journal "Viruses"04-12-2021
Zydus Cadila's Covid vaccine ZyCoV-D to be used in seven states initially
ZyCov-D, which is the first Covid vaccine to be cleared by India's drug regulator for those aged 12 years and above, will only be administered to adults in the seven states02-12-2021
Cadila Healthcare Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate02-12-2021
Cadila Healthcare Ltd - 532321 - Related Party Transactions
The details of Related Party Transactions on consolidated basis for the half year ended on September 30, 202126-11-2021
Govt likely to launch ZyCov-D vaccine in Uttar Pradesh, Bihar, Jharkhand and West Bengal: Sources
ZyCov-D is a needle-free vaccine that is administered intradermally using an applicator, and has been developed by Zydus Cadila26-11-2021
Cadila Healthcare Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation for Loss of Share Certificate by the holder25-11-2021
Cadila Healthcare inks ZyCoV-D commercialisation agreement with Korean firm
Cadila will provide manufacturing license and transfer the Plasmid DNA vaccine technology to Enzychem Lifesciences24-11-2021